TY - JOUR
T1 - A Potential PET Radiotracer for the 5-HT2C Receptor
T2 - Synthesis and in Vivo Evaluation of 4-(3-[18F]fluorophenethoxy)pyrimidine
AU - Kim, Juhyeon
AU - Moon, Byung Seok
AU - Lee, Byung Chul
AU - Lee, Ho Young
AU - Kim, Hak Joong
AU - Choo, Hyunah
AU - Pae, Ae Nim
AU - Cho, Yong Seo
AU - Min, Sun Joon
N1 - Funding Information:
This work was supported by the Korea Health Industry Development Institute (KHIDI HI16C1677) and the National Research Foundation (NRF-2016R1A2B1012277 and NRF-2014M3C1A3054141).
Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/5/17
Y1 - 2017/5/17
N2 - The serotonin 2C receptor subtype (5-HT2C) is an excitatory 5-HT receptor widely distributed throughout the central nervous system. As the 5-HT2C receptor displays multiple actions on various neurotransmitter systems including glutamate, dopamine, epinephrine, and γ-aminobutyric acid (GABA), abnormalities of the 5-HT2C receptor are associated with psychiatric diseases such as depression, schizophrenia, drug abuse, and anxiety. Up to date, three kinds of 5-HT2C PET radiotracers such as [11C]N-methylated arylazepine (1), [11C]WAY-163909 (2), and [18F]fluorophenylcyclopropane (3) have been developed, but they may not be suitable for in vivo 5-HT2C imaging study due to their modest specific binding. Herein, the synthesis and in vivo evaluation of 4-(3-[18F]fluorophenethoxy)pyrimidine [18F]4 as a potential PET radiotracer for the 5-HT2C receptor is described. [18F]4 was synthesized by nucleophilic aromatic substitution of diaryliodonium precursor 17a with a 7.8 ± 2.7% (n = 6, decay corrected) radiochemical yield and over 99% radiochemical purity, showing an 89 ± 14 GBq/μmol specific radioactivity. The in vivo PET imaging studies of [18F]4 with or without lorcaserin, a U.S. Food and Drug Administration approved selective 5-HT2C agonist, demonstrated that [18F]4 exhibits a high level of specific binding to 5-HT2C receptors in the rat brain.
AB - The serotonin 2C receptor subtype (5-HT2C) is an excitatory 5-HT receptor widely distributed throughout the central nervous system. As the 5-HT2C receptor displays multiple actions on various neurotransmitter systems including glutamate, dopamine, epinephrine, and γ-aminobutyric acid (GABA), abnormalities of the 5-HT2C receptor are associated with psychiatric diseases such as depression, schizophrenia, drug abuse, and anxiety. Up to date, three kinds of 5-HT2C PET radiotracers such as [11C]N-methylated arylazepine (1), [11C]WAY-163909 (2), and [18F]fluorophenylcyclopropane (3) have been developed, but they may not be suitable for in vivo 5-HT2C imaging study due to their modest specific binding. Herein, the synthesis and in vivo evaluation of 4-(3-[18F]fluorophenethoxy)pyrimidine [18F]4 as a potential PET radiotracer for the 5-HT2C receptor is described. [18F]4 was synthesized by nucleophilic aromatic substitution of diaryliodonium precursor 17a with a 7.8 ± 2.7% (n = 6, decay corrected) radiochemical yield and over 99% radiochemical purity, showing an 89 ± 14 GBq/μmol specific radioactivity. The in vivo PET imaging studies of [18F]4 with or without lorcaserin, a U.S. Food and Drug Administration approved selective 5-HT2C agonist, demonstrated that [18F]4 exhibits a high level of specific binding to 5-HT2C receptors in the rat brain.
KW - 5-HT receptor
KW - PET radioligands
KW - brain imaging
KW - in vivo
KW - psychiatric disorders
UR - http://www.scopus.com/inward/record.url?scp=85019635949&partnerID=8YFLogxK
U2 - 10.1021/acschemneuro.6b00445
DO - 10.1021/acschemneuro.6b00445
M3 - Article
C2 - 28194935
AN - SCOPUS:85019635949
SN - 1948-7193
VL - 8
SP - 996
EP - 1003
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 5
ER -